Adaptive Biotechnologies Corp Insider Trading Activity
Every SEC Form 4 insider transaction reported for Adaptive Biotechnologies Corp (ADPT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ADPT insiders buying or selling?
In the last 12 months, Adaptive Biotechnologies Corp insiders reported 0 open-market purchases ($0) and 75 sales ($116.6M) — net selling of $116.6M. Since July 2019, Trabud has recorded 397 Form 4 filings for ADPT: 4 buys ($10.2M) and 393 sells ($1.1B).
Source: SEC EDGAR Form 4
What stands out
- No Adaptive Biotechnologies Corp insider made an open-market purchase in the last 12 months; the 75 reported open-market sales totaled $116.6M.
Key Statistics (July 2019 – Oct 16, 2026)
Total Form 4 filings
397
SEC EDGAR
Insider filers
26
Insider buys (4)
$10.2M
Insider sells (393)
$1.1B
Insider sentiment
Net sellingNet insider flow of $1.1B in net selling since July 2019, and $116.6M in net selling over the last 12 months.
Recent ADPT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Julie Rubinstein | President and COO | Sale | 35.6K | $25.18 | $897.4K | SEC ↗ |
| Oct 13, 2026 | Julie Rubinstein | President and COO | Sale | 35.6K | $25.81 | $919.9K | SEC ↗ |
| Oct 8, 2026 | Julie Rubinstein | President and COO | Sale | 35.6K | $26.60 | $948.2K | SEC ↗ |
| Oct 8, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 6.4K | $30.00 | $193.3K | SEC ↗ |
| Oct 6, 2026 | Julie Rubinstein | President and COO | Sale | 35.6K | $28.46 | $1.0M | SEC ↗ |
| Oct 6, 2026 | Francis Lo | Chief People Officer | Sale | 26.8K | $28.28 | $757.7K | SEC ↗ |
| Sep 19, 2026 | Francis Lo | Chief People Officer | Sale | 115.4K | $28.06 | $3.2M | SEC ↗ |
| Sep 17, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 1.2K | $27.00 | $32.3K | SEC ↗ |
| Aug 28, 2026 | Katey Einterz Owen | Director | Sale | 9.6K | $26.00 | $250.0K | SEC ↗ |
| Aug 20, 2026 | Robert Hershberg | Director | Sale | 30.7K | $24.40 | $748.2K | SEC ↗ |
| Aug 20, 2026 | Chad M Robins | CEO and Chairman | Sale | 600.0K | $24.80 | $14.9M | SEC ↗ |
| Aug 20, 2026 | Peter M Neupert | Director | Sale | 124.7K | $25.15 | $3.1M | SEC ↗ |
| Aug 12, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 3.0K | $25.00 | $75.0K | SEC ↗ |
| Aug 3, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 1.3K | $24.00 | $31.2K | SEC ↗ |
| Jul 23, 2026 | Harlan S Robins | Chief Scientific Officer | Sale | 492.4K | $21.89 | $10.8M | SEC ↗ |
| Jul 20, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 5.0K | $23.00 | $115.0K | SEC ↗ |
| Jul 17, 2026 | Francis Lo | Chief People Officer | Sale | 105.8K | $22.59 | $2.4M | SEC ↗ |
| Jul 7, 2026 | Harlan S Robins | Chief Scientific Officer | Sale | 386.2K | $22.01 | $8.5M | SEC ↗ |
| Jul 6, 2026 | Francis Lo | Chief People Officer | Sale | 95.8K | $22.51 | $2.2M | SEC ↗ |
| Jul 6, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 487 | $22.00 | $10.7K | SEC ↗ |
| Jun 30, 2026 | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale | 165.8K | $21.13 | $3.5M | SEC ↗ |
| Jun 29, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 5.0K | $20.50 | $102.5K | SEC ↗ |
| Jun 29, 2026 | Michelle Renee Griffin | Director | Sale | 52.1K | $20.18 | $1.1M | SEC ↗ |
| Jun 18, 2026 | Harlan S Robins | Chief Scientific Officer | Sale | 106.2K | $17.41 | $1.8M | SEC ↗ |
| Jun 15, 2026 | Susan Bobulsky | Chief Commercial Officer, MRD | Sale | 5.0K | $19.00 | $95.0K | SEC ↗ |
Showing the 25 most recent of 397 Form 4 filings for Adaptive Biotechnologies Corp.
Most active ADPT insiders
- Julie Rubinstein58 filings
- Harlan S Robins44 filings
- Chad M Robins38 filings
- Chad M Cohen36 filings
- Francis Lo30 filings
Ask anything about ADPT insider activity
Use Trabud's AI agent to query Adaptive Biotechnologies Corp's Form 4 history in plain English — "Show me ADPT CEO purchases this year" or compare it against any other ticker.
Open the AI agentADPT insider trading FAQ
Are Adaptive Biotechnologies Corp insiders buying or selling?
In the last 12 months, Adaptive Biotechnologies Corp insiders reported 0 open-market purchases ($0) and 75 sales ($116.6M) — net selling of $116.6M. Since July 2019, Trabud has recorded 397 Form 4 filings for ADPT: 4 buys ($10.2M) and 393 sells ($1.1B). Over the full record that is net selling of $1.1B.
How many insiders trade ADPT stock?
26 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Adaptive Biotechnologies Corp. The most recent filing was accepted on Oct 16, 2026.
Where does Trabud get ADPT insider trading data?
All ADPT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.